U
BTAL icon

UBS’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

UBS’s Portfolio BTAL Stock Details BTAL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$16K Sell
842
-231
-22% -$4.48K ﹤0.01% 8268
2014
Q2 		$21K Buy
1,073
+973
+973% +$18.9K ﹤0.01% 8003
2014
Q1 		$2K Sell
100
-1,134
-92% -$21.5K ﹤0.01% 9996
2013
Q4 		$24K Hold
1,234
– – ﹤0.01% 7906
2013
Q3 		$24K Buy
+1,234
New +$24.8K ﹤0.01% 7808

Other funds holding BTAL

ICM
ICC Capital Management Orlando, Florida $760M AUM 17.03% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

UBS's BTAL Position: Q3 2014 in Review

UBS reduced its AGF US Market Neutral Anti-Beta Fund (BTAL) stake by 22% in Q3 2014, selling an estimated $4.48K and leaving 842 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #8268.

UBS first reported a position in BTAL in Q3 2013 and has held it in 5 quarters since. The position peaked at $24K in Q4 2013. 5 funds tracked by Wall St. Rank hold BTAL as of Q3 2014.

  • UBS held 842 shares of AGF US Market Neutral Anti-Beta Fund worth $16K as of Q3 2014.
  • UBS sold 231 AGF US Market Neutral Anti-Beta Fund shares in Q3 2014, an estimated $4.48K.
  • AGF US Market Neutral Anti-Beta Fund made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8268 holding.
  • UBS first reported a position in AGF US Market Neutral Anti-Beta Fund in Q3 2013 and has held it in 5 quarters since.
  • UBS's AGF US Market Neutral Anti-Beta Fund position peaked at $24K in Q4 2013.
  • 5 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.